← THE WIRE
1D EOD · SEP 25 CLOSE
● Consumer · HealthcareGlobeNewswire · BreakingAI-written from GlobeNewswire reporting · checked automatically, not by a personWho answers for this

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Roivant said the FDA approved once-daily LISRAYA for adults with dermatomyositis, with the pill now available in the United States. The approval opens a commercial opportunity, but the company’s latest reported revenue was $8.3M, down 71.6% year over year, against a net margin of -3629.2%.

Keep this report. See new evidence in Following.
The storyAI-written · 1 min read

The FDA has approved Roivant's LISRAYA, a 30 mg once-daily pill for adults with dermatomyositis, the company said Thursday. Roivant announced that the treatment is now available in the U.S., marking the regulatory transition from development to commercial distribution for brepocitinib in this indication.

The approval gives Roivant a marketed product in a rare autoimmune disease, but it arrives against a weak financial base. For the fiscal year ended March 31, 2026, Roivant reported revenue of $8.3M, down 71.6% year over year, and diluted EPS of $-0.54. Its reported net margin was -3629.2%, underscoring that the approval must ultimately translate into prescriptions and revenue rather than serving only as a regulatory milestone.

The direct company exposure is Roivant, whose commercial opportunity now depends on LISRAYA's launch. The mechanism is straightforward: U.S. availability creates the possibility of product revenue from adults with dermatomyositis, while the company's existing losses mean launch execution, patient access and reimbursement will determine how quickly that opportunity affects the financial statements.

Key questions remain around how rapidly physicians will adopt LISRAYA and how much revenue the indication can generate. The latest financial figures therefore provide important context for evaluating the potential commercial contribution from the newly approved product.

The next evidence should come from Roivant's disclosures on launch progress and from its next reported financial results. Investors will need prescription, revenue and cash-burn data to determine whether U.S. availability is producing a meaningful change from the $8.3M revenue base. The timing and scale of any commercial update, as well as management's discussion of LISRAYA's rollout, remain the key open points.

The read · Aug 27

Roivant (ROIV) said the FDA approved once-daily LISRAYA for adults with dermatomyositis, and the pill is now available in the United States.

The approval creates a new revenue pathway, but the financial consequence depends on launch execution that has not yet been quantified. With revenue at $8.3M, down 71.6% year over year, and a net margin of -3629.2%, the next commercial update is more important than the regulatory headline itself.

What could change this view

The trade fails if U.S. availability does not produce measurable prescriptions or revenue, leaving Roivant’s sharply negative profitability profile unchanged.

CoverageSource: GlobeNewswire · Published here THU, AUG 27 · 3:29 PM ET · the only report in this recordHow this is decided →

Named in the readROIV -0.9%1D EOD · SEP 25
GLOBENEWSWIRE / FILE
The chart · ROIVTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
Story timeline0 later reports

Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.

You are reading this report

No later reports linked yet.

Follow this story to find new evidence in your Following desk.

Since this story · named here, equal weight · 1D EOD-4.7%
AUG 27 · first close after publicationSEP 25

Price context does not establish that the story caused the move.

▲ The case it holds

FDA approval and immediate U.S. availability give Roivant a concrete commercial product that could begin reversing the $8.3M revenue base.

▼ The case it breaks

The bear case is that approval produces little near-term financial relief because the announcement supplies no launch forecast, prescription data or pricing information while diluted EPS remains $-0.54.

Receipts
Research, not advice.

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →

SharePost on X
READER EVIDENCEOpens with the recordFollow the story to be told when it moves.